Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologyAetna Growth Hormone Coverage Update | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedAetnaPolicy 0170

    Growth Hormone (GH) and Growth Hormone Antagonists

    Customize your policy alerts

    Sign up for Aetna Policy 0170 alerts

    Get alerted when Policy 0170 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage rules for somatropin products, weekly GH formulations, Serostim, and related GH antagonists for Aetna commercial medical plans; includes indications, initial and continuation criteria, and precertification requirements that affect participating providers and members.

    Policy Summary
    PayerAetna
    PolicyGrowth Hormone (GH) and Growth Hormone Antagonists
    Policy CodePolicy 0170
    Change TypeLabel expansions and added product approvals
    Effective DateAug 14, 1997
    Last ReviewJul 28, 2023
    Next Review DateMar 28, 2024
    Key ActionObtain prior authorization/precertification for Serostim or Somavert and submit required documentation (Statement of Medical Necessity) when applicable.
    SourceLink
    POLICY UPDATE CHANGES

    FDA approved once-weekly somapacitan (Sogroya) for adult growth hormone deficiency and subsequently expanded labeling to pediatric patients aged 2.5 years and older.

    FDA approved once-weekly lonapegsomatropin (Skytrofa) for pediatric GHD (age ≥1 year, weight ≥11.5 kg) based on the phase 3 heiGHt trial.

    multiplebrands listed
    precertification requiredprecert required
    ≥1 yrSkytrofa pediatric age
    ≥2.5 yrSomapacitan pediatric age
    ~70+experimental indications
    07/28/2023last review

    Coverage Criteria and Indications

    Initial Therapy - Pediatric GH Deficiency

    Covered when EITHER of the following pathways is met:

    Initial pediatric GH deficiency entry: Either: (A) Neonatal diagnosis of GH deficiency with supporting medical records (e.g., hypoglycemia with random GH, evidence of multiple pituitary hormone deficiency, chart notes, or MRI); OR (B) All of: (1) Either two pretreatment pharmacologic provocative GH tests with both peak GH < 10 ng/mL, OR a documented pituitary/CNS disorder and pretreatment IGF-1 > 2 SD below the mean; (2) If age at initiation < 2.5 years: pretreatment height > 2 SD below the mean and slow growth velocity; (3) If age at initiation >= 2.5 years: either pretreatment height > 2 SD below the mean AND 1-year height velocity > 1 SD below the mean, OR 1-year height velocity > 2 SD below the mean; (4) Epiphyses are open.

    Per Somatropin products pediatric criteria

    Initial Therapy - Other Pediatric Indications

    Selected pediatric indications covered when ALL indication-specific entry requirements are met:

    Small for Gestational Age (SGA): Member born SGA who failed to manifest catch-up growth by age 2 (pretreatment height >2 SD below mean), pretreatment age >=2 years at initiation, epiphyses open, and meeting birth-size criteria per labeling; therapy initiated and dosed per product labeling (e.g., Genotropin guidance).
    Policy Summary
    PayerAetna
    PolicyGrowth Hormone (GH) and Growth Hormone Antagonists
    Policy CodePolicy 0170
    Change TypeLabel expansions and added product approvals
    Effective DateAug 14, 1997
    Last ReviewJul 28, 2023
    Next Review DateMar 28, 2024
    Key ActionObtain prior authorization/precertification for Serostim or Somavert and submit required documentation (Statement of Medical Necessity) when applicable.
    SourceLink
    On This Page
    Coverage Criteria and IndicationsRelevant Codes and ThresholdsAuthorization, Documentation, and Monitoring RequirementsBackground and ScopePolicy Revisions and Notes

    SGA criteria and dosing considerations

    Turner syndrome: Member has confirmed Turner syndrome, height SDS typically <= -2, decision individualized by height and growth velocity; supra-physiological GH dosing commonly used (typical 0.045–0.050 mg/kg/day) and baseline evaluations documented (bone age, growth velocity).

    Turner dosing rationale

    SHOX deficiency: Member has molecularly proven SHOX mutation or deletion with short stature meeting entry growth criteria; evidence of benefit from RCTs demonstrating increased height velocity and height SDS with GH.

    Require genetic confirmation when available

    Prader-Willi syndrome (PWS): Member has genetically confirmed PWS; GH may be used to improve growth and body composition at recommended pediatric dose ~0.035 mg/kg/day; evaluate and manage obesity and screen for upper airway obstruction/sleep apnea prior to initiation; avoid use in patients who are severely obese or have severe respiratory impairment per product labeling.

    Safety constraints and monitoring per labeling

    Other pediatric indications (examples): Consider GH for selected congenital/rare conditions (e.g., 18p deletion syndrome, Noonan syndrome, Silver-Russell/SRS) when condition is documented and indication-specific entry criteria (genetic confirmation, height/growth velocity, bone age, open epiphyses) are met as described in policy and consensus guidance.

    Use is indication-specific and requires documentation

    Initial / Continuation Therapy - Adult GH Deficiency

    Covered when ANY one of the defined adult diagnostic pathways is met:

    Two-test biochemical confirmation: Member has two pretreatment pharmacologic provocative GH tests demonstrating deficient responses (examples: ITT or alternative peak GH <= 5 ng/mL; macimorelin peak < 2.8 ng/mL; glucagon thresholds per BMI as specified) AND pretreatment IGF-1 low (0 to -2 SD below mean) AND current IGF-1 not elevated for age/gender.

    Typical pathway for adult-onset AGHD

    Single-test plus low IGF-1: Member has one pretreatment provocative GH test with deficient response (per test-specific cutoffs) AND pretreatment IGF-1 > 2 SD below mean AND current IGF-1 not elevated for age/gender.

    Alternate pathway when IGF-1 strongly low

    Organic hypothalamic-pituitary disease: Member has organic hypothalamic-pituitary disease with >=3 documented pituitary hormone deficiencies AND pretreatment IGF-1 > 2 SD below mean AND current IGF-1 not elevated for age/gender (in many such adults only one provocative test is required).

    Clinical pathway that may obviate repeat stimulation testing

    Other pathways: Member has genetic/structural hypothalamic-pituitary defects or childhood-onset GHD with congenital CNS/pituitary abnormality and current IGF-1 not elevated for age/gender as alternative diagnostic bases for adult therapy initiation.

    Per policy appendices and adult criteria

    Initial/Continuation Therapy - Serostim (HIV wasting)

    Serostim (somatropin) is covered for HIV-associated wasting/cachexia when ALL criteria are met:

    Serostim initial: Member has a diagnosis of HIV-associated wasting or cachexia; AND member is currently on antiretroviral therapy; AND member has trialed alternative therapies with suboptimal response or has contraindication/intolerance to alternatives; AND pretreatment BMI was < 18.5 kg/m2 prior to initiating Serostim.

    Continuation requires current BMI < 27 kg/m2 and ongoing receipt of Serostim (not samples)

    Initial/Continuation Therapy - Somapacitan-beco (Sogroya)

    Somapacitan-beco (Sogroya) coverage mirrors standard GH diagnostic pathways — separate pediatric and adult entries:

    Sogroya pediatric initial: Either: (A) Neonatal diagnosis of GH deficiency with supporting records; OR (B) All of: two pretreatment provocative GH tests both peak < 10 ng/mL OR documented pituitary/CNS disorder plus pretreatment IGF-1 > 2 SD below mean; plus pretreatment height/height velocity criteria and open epiphyses. Applicable for members >= 2.5 years per product labeling.

    Pediatric somapacitan age threshold per labeling

    Sogroya adult initial: Any of: two provocative GH tests with deficient responses per test-specific cutoffs AND low pretreatment IGF-1 (0 to -2 SD); OR one provocative test with deficient response AND pretreatment IGF-1 <-2 SD; OR organic hypothalamic-pituitary disease with >=3 deficiencies and low IGF-1; OR genetic/structural defects or childhood-onset GHD with congenital abnormality — and current IGF-1 not elevated for age/gender.

    Dose initiation typically 1.5 mg weekly and titration by IGF-1 with max 8 mg weekly

    Initial/Continuation Therapy - Lonapegsomatropin-tcgd (Skytrofa)

    Lonapegsomatropin-tcgd (Skytrofa) coverage for pediatric GHD (members >= 1 year) requires EITHER neonatal diagnosis OR the specified diagnostic/anthropometric pathway:

    Skytrofa pediatric initial: Either: (A) Neonatal diagnosis of GH deficiency with supporting records; OR (B) All of: two pretreatment provocative GH tests both peak < 10 ng/mL OR documented pituitary/CNS disorder plus pretreatment IGF-1 > 2 SD below mean; for <2.5 years: pretreatment height >2 SD below mean and slow growth velocity; for >=2.5 years: pretreatment height >2 SD below mean AND 1-year HV >1 SD below mean OR 1-year HV >2 SD below mean; AND epiphyses open. Member must be >=1 year of age and meet weight criteria per labeling.

    Continuation requires open epiphyses and growth rate >2 cm/year unless justified

    Skytrofa continuation: Epiphyses open (confirmed by X-ray or X-ray not available) AND member’s growth rate > 2 cm/year unless documented clinical reason for lack of efficacy (e.g., <1 year on treatment or nearing final height).

    Per Skytrofa continuation rules

    Somapacitan (Sogroya) — selected adult diagnostic criteria snippets

    Selected adult diagnostic pathways and thresholds used with somapacitan (examples):

    Glucagon stimulation pathway (example): Glucagon stimulation test with peak GH <= 1.0 ng/mL in members with BMI >= 25 kg/m2 and low pretest probability OR BMI > 30 kg/m2, combined with pretreatment IGF-1 more than 2 SD below mean and current IGF-1 not elevated for age/gender.

    BMI-stratified glucagon cutoffs per policy

    Organic hypothalamic-pituitary disease pathway: Member has organic hypothalamic-pituitary disease with >=3 documented pituitary hormone deficiencies AND pre-treatment IGF-1 > 2 SD below the mean AND current IGF-1 not elevated for age/gender.

    Alternative non-stimulation diagnostic pathway

    Structural/genetic defects pathway: Member has genetic or structural hypothalamic-pituitary defects and current IGF-1 not elevated for age/gender (diagnostic alternative to stimulation testing).

    Used when structural/genetic diagnosis established

    Lonapegsomatropin (Skytrofa) — Initial and Continuation pediatric criteria

    Skytrofa pediatric initial and continuation summary (members ≥1 year):

    Initial approval (A): Neonatal diagnosis of GH deficiency documented in medical records (e.g., hypoglycemia with random GH, multiple pituitary hormone deficiency, MRI).

    Neonatal pathway

    Initial approval (B): All: (1) Either two provocative GH tests both peak <10 ng/mL OR documented pituitary/CNS disorder plus pretreatment IGF-1 >2 SD below mean; (2) age-specific pretreatment height and growth velocity criteria (see pediatric GHD rules); (3) for >=2.5 yrs, height/velocity thresholds as specified; (4) epiphyses open.

    Anthropometric and testing pathway

    Continuation: Epiphyses open (confirmed by X-ray or X-ray unavailable) AND member’s growth rate >2 cm/year unless documented clinical reason for lack of efficacy.

    Continuation criteria

    Macimorelin (Macrilen) — adult diagnostic test criteria

    Macimorelin (Macrilen) stimulation testing is medically necessary when ALL criteria are met:

    Macimorelin test criteria: Member is >= 18 years of age; AND BMI <= 40 kg/m2; AND test is ordered by an endocrinologist; AND member has contraindication to ALL other diagnostic tests for AGHD (insulin tolerance, glucagon, arginine, clonidine, levodopa, or arginine+levodopa); AND single-dose macimorelin does not exceed 0.5 mg/kg.

    Macimorelin diagnostic cutpoint: stimulated GH < 2.8 ng/mL confirms AGHD

    Pegvisomant (Somavert) — acromegaly

    Pegvisomant (Somavert) is covered for acromegaly when ALL initial approval criteria are met; continuation requires biochemical response:

    Pegvisomant initial: Member has elevated pretreatment IGF-1 for age/gender based on lab reference range; AND member had an inadequate or partial response to surgery or radiotherapy OR there is a clinical reason why surgery/radiotherapy has not been performed.

    Pegvisomant indicated after inadequate first-line therapies

    Pegvisomant continuation: Member's IGF-1 level has decreased or normalized since initiation of therapy; monitoring includes periodic IGF-1 and liver function tests and pituitary MRI surveillance per labeling.

    LFT monitoring before and monthly for first 6 months, then every 6 months

    Initial diagnostic criteria for adult GH deficiency

    Diagnostic confirmation and initiation of adult GH therapy require clinical context plus biochemical testing:

    Adult AGHD diagnostic criteria: Member has clinical evidence of hypothalamic-pituitary disease or prior cranial irradiation OR a history of childhood-onset GHD requiring retesting; AND biochemical confirmation of GH deficiency by approved provocative testing (e.g., ITT) or validated alternatives (macimorelin, arginine ± GHRH, glucagon) using the test-specific cutoffs; AND baseline and follow-up IGF-I measurements to guide dosing and titration.

    In adults with history of hypothalamic-pituitary disease or cranial irradiation generally only one provocative test is needed; childhood-onset cases usually require two tests unless profoundly low IGF-1

    Adult GH dosing and monitoring

    Adult GH dosing and monitoring expectations for initiation and titration:

    Adult GH starting and titration: Start at a very low dose (e.g., 0.1 to 0.4 mg/day) and increase gradually based on clinical response and serum IGF‑I measured monthly; maintain IGF‑I within the age‑ and sex‑adjusted normal range; maximal doses vary by age (up to ~1.75 mg/day for <35 years; up to ~0.875 mg/day for >35 years).

    IGF-1 guided titration and monthly assessment recommended

    GH for short bowel syndrome

    Zorbtive (GH) for short bowel syndrome (SBS) — coverage when used with optimal nutritional support:

    Zorbtive for SBS: Member has short bowel syndrome dependent on intravenous parenteral nutrition for nutritional support AND GH (Zorbtive) will be used in conjunction with optimal management/nutritional support; dosing approximately 0.1 mg/kg/day subcutaneously for up to 4 weeks (maximum 8 mg/day).

    Treatment duration limited to 4 weeks per labeling; used with specialized nutritional program

    Once-weekly somapacitan (Sogroya)

    Somapacitan (Sogroya) — once-weekly adult GH replacement coverage highlights:

    Somapacitan adult therapy: Somapacitan is FDA-approved for once-weekly replacement therapy in adults with GHD; initiation dose typically 1.5 mg once weekly for treatment‑naive or switching patients with titration every 2–4 weeks by ~0.5–1.5 mg increments guided by clinical response and IGF‑I SDS; maximum recommended 8 mg weekly. Clinical trials demonstrated truncal fat reduction and comparable safety/tolerability to daily GH with IGF‑I SDS used for dose titration.

    Monitoring of IGF-I SDS and clinical response required

    Indications and key monitoring/usage considerations

    Indications and monitoring considerations (summary of covered uses and safety signals):

    Covered indications summary: GH replacement is covered for established indications (pediatric GHD, adult GHD, Turner syndrome, Prader-Willi syndrome, SGA, SHOX deficiency, certain genetic/structural disorders) when the diagnostic and anthropometric criteria are met; once-weekly agents (somapacitan, lonapegsomatropin) have product-specific age/weight thresholds and require IGF‑I guided titration.

    Refer to product-specific sections for exact age and testing requirements

    Monitoring and safety: Monitor IGF‑I for dose titration and safety; for pegvisomant monitor LFTs before and monthly for first 6 months then every 6 months and obtain pituitary MRI surveillance per labeling; in PWS evaluate and manage airway/obesity prior to initiation and monitor closely for respiratory events.

    Safety signals include transaminase elevations with pegvisomant (~9% in long-term reports) and PWS respiratory risk

    Cystic fibrosis — evidence and recommendation

    Cystic fibrosis — evidence summary and policy conclusion:

    CF evidence summary: Randomized and quasi-randomized trials (8 trials, 291 participants) show short-term improvements in anthropometrics (height, weight, lean body mass) and some pulmonary measures but quality is low-to-very-low, trials small and short-term, and no prospective studies assessed final adult height; routine long-term use is not established.

    Policy advises more rigorous long-term RCTs prior to routine use

    Prader-Willi syndrome — approval and safety constraints

    Prader-Willi syndrome — covered when genetic confirmation and safety evaluations are documented:

    PWS coverage and safety: Member has genetically confirmed Prader‑Willi syndrome; GH therapy may be used to increase growth velocity and improve body composition at recommended pediatric dosing (~0.035 mg/kg/day); prior to initiation evaluate for upper airway obstruction and sleep apnea and manage obesity; GH is contraindicated in PWS patients who are severely obese or have severe respiratory impairment per product labeling.

    Monitor for airway symptoms and interrupt treatment for obstruction or infection

    SHOX deficiency — evidence

    SHOX deficiency — entry requires molecular confirmation plus growth criteria:

    SHOX-D coverage: Member has molecularly proven SHOX mutation/deletion and short stature meeting growth-entry criteria; RCT evidence demonstrates significant increases in height velocity and height SDS with GH therapy comparable to Turner syndrome outcomes.

    Genetic confirmation recommended for prior authorization

    SGA — efficacy and metabolic risk considerations

    SGA — covered when entry criteria and monitoring are met; metabolic risks considered:

    SGA initial coverage: Member born small for gestational age who failed to manifest catch-up growth by age 2 (pretreatment height >2 SD below mean), pretreatment age >=2 years at initiation, epiphyses open, and meeting any birth-size criteria per labeling; dosing per product label (e.g., Genotropin 0.48 mg/kg/week) and monitoring for insulin resistance and metabolic effects is required.

    Long-term metabolic effects uncertain; surveillance recommended

    SRS (Silver-Russell) guidance: For SRS (considered under SGA), international consensus recommends GH when height SDS <= -2.5 and age >2–4 years (start dose ~35 µg/kg/day), use lowest effective dose, and stop when height velocity <2 cm/year over 6 months and bone age >14 (female) or >17 (male).

    Exemptions allow earlier start in severe hypoglycemia/malnutrition/hypotonia

    Noonan syndrome — approval and clinical entry criteria

    Noonan syndrome — covered when short stature and study-like inclusion criteria are documented:

    Noonan syndrome coverage: Member has confirmed Noonan syndrome with short stature (height SDS <= -2) and meets study-like entry criteria (prepubertal status, bone age without significant acceleration, fasting plasma glucose <= 120 mg/dL); dosing in trials up to 0.033–0.066 mg/kg/day with adjustment after 2 years; evidence of benefit on final height in RCTs supports coverage when criteria met.

    Document baseline bone age, growth velocity, and glucose status

    SRS — consensus practical guidance

    Silver‑Russell syndrome (SRS) — consensus guidance applied under SGA indication:

    SRS consensus guidance: International consensus recommends GH for children with SRS under the SGA indication (height SDS <= -2.5; age >2–4 years) with starting dose around 35 µg/kg/day using the lowest effective dose; consider earlier initiation for severe hypoglycemia, malnutrition, or severe hypotonia; stop when height velocity <2 cm/year over 6 months and bone age >14 (female) or >17 (male).

    Policy applies SRS guidance within SGA coverage

    Turner syndrome — dosing considerations

    Turner syndrome — coverage requirements and typical dosing considerations:

    Turner syndrome coverage: Member has confirmed Turner syndrome with short stature sufficient to warrant therapy; GH may be started when height SDS < -2 and dosing is often supra‑physiological (typical 0.045–0.050 mg/kg/day); document baseline height, growth velocity and bone age prior to initiation.

    Consider adjunct oxandrolone in selected cases per literature

    18p deletion syndrome — evaluation and individualized therapy

    Other rare indications — individualized consideration where evidence/case reports support endocrine evaluation and therapy:

    18p deletion syndrome: Consider endocrine evaluation and GH therapy for patients with confirmed 18p deletion syndrome who have short stature and documented GH deficiency or endocrine findings supporting treatment; evidence is case-based and management individualized.

    Require genetic/cytogenetic documentation and baseline endocrine evaluation

    Other indications — coverage stance (summarized)

    Summary coverage stances for additional indications (high-level):

    Select other indications: Glucocorticoid‑induced growth failure: GH may be considered with documented GC exposure, poor growth metrics, and monitoring (studies show mean growth rate doubling after 12 months); HIV‑associated lipodystrophy: considered experimental/investigational; Idiopathic short stature (ISS): not considered a disease by Aetna and generally not covered; Acutely catabolic/critically ill states and ALS: not recommended due to harm or lack of benefit.

    Refer to detailed policy sections for each indication

    Other indications — evidence summaries and insurer stance

    Evidence summaries and insurer stance for selected other indications:

    Glucocorticoid-induced growth failure: Evidence (National Cooperative Growth Study subset, n=83) shows GH increased growth rate and height SDS with monitoring of IGF‑I, IGFBP‑3, glucose and HbA1c; consider therapy when GC-induced growth suppression present and benefits outweigh risks.

    Document GC dose/duration and monitoring plan

    HIV-associated lipodystrophy: Systematic reviews indicate GH-axis agents reduce visceral adipose tissue and increase lean mass but produce adverse effects; Aetna considers GH experimental/investigational for this indication.

    Not routinely covered

    Idiopathic short stature (ISS): Although GH can modestly increase adult height (2–7 cm), Aetna considers ISS an enhancement rather than disease; coverage is generally not available under plans covering disease/illness/injury only.

    Contractual noncoverage rather than medical necessity

    Implant osseointegration (preclinical evidence)

    Preclinical evidence summaries (example):

    Implant osseointegration (preclinical): Pre-clinical animal studies indicate increased bone-to-implant contact in a majority of trials; pooled mean difference favored GH in animal models but human trials are lacking and clinical application requires controlled human studies.

    Preclinical evidence only

    Rotator cuff repair (RCT evidence)

    Rotator cuff repair — randomized human trial evidence summary:

    Rotator cuff repair evidence: One multicenter randomized trial of sustained‑release rhGH (once‑weekly for 3 months) after arthroscopic rotator cuff repair showed no statistically significant improvement in healing rate, functional scores, ROM, or pain versus control; therefore routine use is not supported by current RCT evidence.

    Not medically necessary outside trials

    IVF / Endometrial receptivity / Poor ovarian responders (systematic reviews and RCTs)

    IVF / endometrial receptivity / poor ovarian responders — heterogeneous evidence:

    IVF / POR evidence summary: Multiple RCTs and meta-analyses report heterogeneous results; GH adjunctive therapy may increase oocyte yield, endometrial thickness, and clinical pregnancy rates in poor ovarian responders but effects on live-birth rate are inconsistent and certainty is low to very low; protocols, doses and timing vary widely across studies.

    Require indication-specific protocol and justification for prior authorization

    Oral health in children with GHD

    Oral health in children with GHD — observational findings:

    Dental and craniofacial findings: Observational studies in children with GHD (total n~465 across studies) report delayed dental maturity (1–2 years), abnormal craniofacial morphology with reduced mandibular dimensions and increased Angle’s Class II occlusion; longitudinal pre/post-GH treatment data are limited.

    Clinical significance and implications for dental care require further study

    Neurotrophic / retinal injury (preclinical)

    Neurotrophic / retinal injury — preclinical mechanistic evidence:

    Retinal injury preclinical: Preclinical models show chronic GH administration after excitotoxic retinal injury improved retinal layer thickness and upregulated genes involved in synaptogenesis and pro-survival pathways, suggesting potential neurotrophic/regenerative effects warranting further investigation.

    Preclinical data only; not clinical coverage criteria

    Primary IGF‑1 deficiency (neurosecretory defect)

    Primary IGF‑1 deficiency (neurosecretory defect) — clinical characterization relevant to consideration of therapy:

    Primary IGF-1 deficiency assessment: In prepubertal children with isolated short stature, primary IGF‑1 deficiency is defined by IGF‑1 <= -2 SDS without GH deficiency and without secondary causes; evaluation should include IGF‑1, GH secretion assessment, pubertal status, birth size (SGA vs AGA), and bone age to inform management decisions.

    Some cohorts report ~20% prevalence among isolated SS children

    Other/Investigational Indications — generally not established

    Other/Investigational indications — not established for routine coverage:

    Investigational indications: Conditions listed in the policy (e.g., retinal injury, IUGR, ALS, anti‑aging, many miscellaneous adult conditions, some skeletal dysplasias) are considered investigational or lacking consistent evidence and are not supported for routine coverage unless elsewhere in the policy an established indication/criteria are met.

    Require prior authorization with indication-specific evidence if requested

    Conditions with limited supportive evidence

    Conditions with limited supportive evidence — small series where GH may help:

    PHP-Ia / PPHP with documented GHD: Small series indicate prepubertal children with PHP‑Ia and documented GH deficiency may increase height SDS and growth velocity with rhGH; therapy should be initiated early and documented with pretreatment GH deficiency and prepubertal status.

    Evidence limited to small cohorts

    PHP-Ia (preliminary evidence)

    PHP‑Ia — preliminary evidence and recommended documentation when considered:

    PHP-Ia evidence: Small series (n=8 prepubertal children with GH deficiency) showed increases in height SDS and HV during rhGH therapy but limited effect on near‑adult height; document GH deficiency and consider early initiation given limited therapeutic window.

    Prior authorization should include rationale and pre-treatment metrics

    Crohn's disease (insufficient evidence)

    Crohn's disease — randomized trial evidence does not support routine use:

    Crohn's disease with short stature: Small randomized trial (n=7) of GH at 0.05 mg/kg/day did not show statistically significant stimulation of growth; observed responses varied and nutritional optimization is integral—GH alone is not established for this indication.

    Consider not medically necessary absent additional supportive evidence and nutritional therapy

    Skeletal dysplasias (limited benefit)

    Skeletal dysplasias — limited benefit noted in available literature:

    Skeletal dysplasias: GH therapy has been tried in conditions such as achondroplasia with modest growth acceleration but insufficient impact to approach normal adult height; evidence is limited and routine use is not supported to normalize stature.

    Not expected to normalize adult height

    Thalassemia (small RCT evidence)

    Thalassemia — small RCT evidence with modest short-term growth effects:

    Thalassemia trial evidence: One small parallel RCT (n=20) in children with homozygous beta thalassemia showed modest improvements in height velocity and height SDS over 1 year but no data on final height; fasting glucose modestly higher in GH group; longer trials needed before routine use.

    Evidence moderate certainty but limited by sample size and duration

    Traumatic brain injury (preliminary evidence)

    Traumatic brain injury (TBI) — preliminary data support further study but not routine coverage:

    TBI with altered GH secretion: Preliminary studies and systematic reviews (including small RCTs) suggest rhGH replacement started in the chronic phase post‑TBI may improve cardiorespiratory fitness, some cognitive domains, depression symptoms and quality of life; evidence is limited and larger trials are needed before routine coverage.

    Consider only in trial settings or with detailed justification

    Testing criteria (children and adults)

    Testing criteria — recommendations for provocative testing in children and adults:

    Children - provocative testing: Exclude hypothyroidism before testing; when testing children with suspected isolated GHD (no other pituitary deficiencies) perform two different provocative tests (e.g., clonidine, arginine, glucagon) to establish diagnosis.

    Per UpToDate and policy guidance

    Adults - when testing not required: In adults testing for GHD is not required when there are three or more pituitary hormone deficiencies with low IGF‑1 or in selected congenital structural/genetic conditions listed in Appendix C.

    Appendix C lists congenital defects where testing may be unnecessary

    Adults - when testing required: Testing is required for acquired causes (skull-base lesions, pituitary adenoma, craniopharyngioma, prior cranial irradiation, TBI, infiltrative disease, surgery to sella region, infections, infarction/hemorrhage, empty sella, hydrocephalus, idiopathic causes) as detailed in Appendix C.

    Refer to policy Appendix C for full list

    FDA-approved indications and payer note

    FDA‑approved indications and payer note (summary):

    FDA-approved indications list: Brands and FDA‑approved indications are tabulated (e.g., adult GHD: macimorelin for diagnosis; pediatric GHD: Genotropin, Humatrope, Norditropin, Nutropin AQ, Omnitrope, Saizen, Zomacton; Prader‑Willi: Genotropin, Norditropin, Omnitrope; Turner: Genotropin, Humatrope, Norditropin, Nutropin AQ, Omnitrope, Zomacton; SGA: multiple brands; SHOX deficiency: Humatrope, Zomacton; short bowel syndrome: Zorbtive; HIV wasting: Serostim). Aetna footnote: GH for idiopathic short stature is not covered under many plans.

    Appendix L reference

    Aetna considers all indications not explicitly listed in this policy for growth hormone products to be experimental and investigational. This applies to somatropin brands and related agents unless a specific indication and coverage criteria are provided elsewhere in the bulletin. (See policy sections for product‑specific criteria and appendices.)

    The policy lists a broad set of indications that Aetna considers experimental and investigational. Examples include but are not limited to: adolescent transgender transitioning to male, amyotrophic lateral sclerosis (ALS), anti‑aging, burn injuries, chronic catabolic states (including inflammatory bowel disease), chronic fatigue syndrome, congestive heart failure, Crohn’s disease, HIV‑associated lipodystrophy, hypochondroplasia, hypophosphatemia (X‑linked), implant osseointegration, rotator cuff repair/healing, improvement of oral health, intra‑uterine growth restriction not meeting SGA criteria, infertility/IVF adjuncts, neurosecretory dysfunction/IGF‑1 deficiency, skeletal dysplasias (e.g., achondroplasia), traumatic brain injury, thalassemia, and many other listed conditions. These uses are considered investigational because effectiveness has not been established in the published evidence summarized in the policy.

    Growth hormone therapy is contraindicated in patients with active malignant disease. Other important exclusions per accepted labeling include benign intracranial hypertension (pseudotumor cerebri) and proliferative or pre‑proliferative diabetic retinopathy. The policy also notes hypersensitivity to GH or excipients and recommends discontinuation of GH if pregnancy is confirmed.

    In pediatric patients, GH is contraindicated in the presence of active malignancy. The policy further highlights controversy and cautions regarding the safety of GH within the first one to two years following treatment for leukemia, medulloblastoma, ependymoma, or other tumors; clinicians should document oncologic history and consider safety implications when evaluating post‑treatment children for GH therapy.

    For Prader‑Willi syndrome (PWS), the FDA labeling and policy warn of serious respiratory risks. GH is contraindicated in PWS patients who are severely obese or who have severe respiratory impairment. The policy requires evaluation for upper‑airway obstruction and sleep apnea before initiation and ongoing monitoring; treatment should be interrupted for signs of airway compromise or respiratory infection.

    Use of GH for acute catabolic states (for example, critically ill, perioperative, or severe burn patients) is explicitly not recommended. Randomized trials in critically ill populations demonstrated an increased mortality signal with GH treatment, and such indications should be avoided outside of controlled clinical research.

    The policy summarizes trial evidence showing that GH for amyotrophic lateral sclerosis (ALS) does not provide survival or functional benefit. Given the lack of efficacy, GH use for ALS is not supported outside of research settings.

    Administration of GH as an anti‑aging therapy in otherwise healthy older adults is not supported by the evidence and is not FDA‑approved. Published trials report only modest body‑composition changes with increased adverse events; routine use for rejuvenation is not recommended and should be limited to clinical trials.

    Aetna considers GH treatment for HIV‑associated lipodystrophy to be experimental and investigational. Although some trials of GH‑axis agents have shown reductions in visceral adipose tissue and increases in lean body mass, effects on clinical outcomes, safety signals, and durability are uncertain; GH for this indication may be denied.

    Use of GH as an adjunct to in‑vitro fertilization (IVF) or to improve endometrial receptivity in routine IVF is not supported by high‑certainty evidence. Systematic reviews and meta‑analyses report heterogeneous results across poor‑responder and thin endometrium populations, with inconsistent effects on live‑birth rates; routine use is considered investigational without clear protocol‑level justification.

    Growth hormone therapy for intrauterine growth restriction (IUGR) is unsupported by controlled trial evidence. A Cochrane review found no eligible trials reporting clinical fetal or perinatal outcomes, and clinical use for IUGR is not established.

    In skeletal dysplasias (for example, achondroplasia), GH may produce some increase in growth velocity but typically does not produce sufficient gain to approach normal adult height. Therefore GH is generally not expected to normalize stature in these conditions and is considered of limited benefit.

    Aetna does not cover growth hormone for idiopathic short stature (ISS). The policy clarifies that ISS is not considered an illness or disease under many benefit plans; accordingly coverage for GH in ISS is typically unavailable and denials in that context are contractual rather than medical‑necessity based.

    The cited reference material in the policy includes prescribing information, clinical trials, and systematic reviews that support the policy text. These reference‑only sections summarize sources but do not, by themselves, establish additional exclusions beyond those explicitly stated in the main policy sections.

    This Clinical Policy Bulletin provides a general description of Aetna’s coverage approach and is intended to assist in administering plan benefits. It does not constitute an insurance contract or guarantee of payment; coverage is subject to the member’s benefit plan terms and any applicable medical necessity determinations.

    The policy considers additional laboratory testing to identify “partial” GH deficiency or to diagnose other GH‑axis bioactivity abnormalities in children without classic GH deficiency to be not medically necessary. This includes overnight inpatient testing for spontaneous GH secretion. Measurement of IGF‑I is considered appropriate for assessing adequacy of therapy, but diagnosis must be corroborated by provocative GH testing.

    Because Aetna does not consider idiopathic short stature to be an illness or disease, the policy states that GH treatment for ISS is typically not covered under benefit plans that limit coverage to treatment of disease, illness, or injury. Such denials reflect benefit design rather than medical necessity criteria.

    Use of GH to treat age‑related declines in endogenous GH — marketed as a rejuvenation strategy — is not supported by long‑term evidence of safety or sustained clinical benefit. The policy notes small, short‑term improvements in lean mass and bone mass but highlights unknown long‑term oncologic and other risks; this use is not recommended.

    For cystic fibrosis, randomized trials report short‑term improvements in anthropometric measures (height, weight, lean body mass) and some pulmonary function outcomes; however, evidence quality is low and no prospective studies have evaluated linear growth to final adult height. Routine rhGH use in CF to improve final height or long‑term clinical outcomes is not established.

    GH for anti‑aging in otherwise healthy elderly persons is unsupported. Randomized trials show limited benefit and increased adverse events; routine clinical use for anti‑aging is not recommended and should be confined to clinical research.

    The evidence for GH as a treatment for chronic fatigue syndrome is insufficient. Systematic reviews identify only small, inconclusive trials and conclude that effectiveness has not been demonstrated, so GH for chronic fatigue syndrome is considered not medically necessary.

    Aetna considers GH for idiopathic short stature (ISS) to be not medically necessary in most cases. While GH can produce modest increases in final height (generally 2–7 cm in trials), ISS is regarded as an enhancement of appearance rather than treatment of disease; coverage is therefore not supported absent a covered diagnosis.

    Randomized controlled evidence does not support routine administration of rhGH after rotator cuff repair to improve healing or clinical outcomes. A multicenter RCT of sustained‑release rhGH found no statistically significant benefit on repair failure rate, functional scores, range of motion, or pain; GH for this indication is therefore not supported outside of further research.

    Long‑term GH therapy for a variety of miscellaneous adult conditions (such as age‑related bone loss without hypopituitarism, chronic catabolic states, obesity, osteoporosis unrelated to GH deficiency, or other non‑GH‑deficiency indications) is not supported by consistent evidence of clinically meaningful benefit and is not routinely recommended.

    In children with Crohn’s disease and short stature, randomized trial data are limited and at the doses studied did not demonstrate a statistically significant stimulation of growth. The policy recommends considering nutritional optimization and addressing inflammatory disease control before pursuing GH, and regards GH monotherapy for Crohn’s‑related growth failure as not established.

    Before concluding that an indication is not medically necessary, refer to the main policy sections for the specific Not Medically Necessary criteria. The policy directs reviewers to the established coverage criteria and to supporting documentation requirements when assessing requests for indications that are uncommon or have limited evidence.

    Relevant Codes and Thresholds

    Related CPT and lab codesCPT
    80428Growth hormone stimulation panel (e.g., arginine infusion, l-dopa administration) or growth hormone suppression panel (glucose administration)
    80430Growth hormone stimulation panel (continued)
    82943Glucagon
    83003Growth hormone, human (HGH) (somatotropin)
    84305Somatomedin
    84436Thyroxine; total
    HCPCS codes covered if selection criteria are metHCPCSCovered
    J2940Injection, somatrem, 1 mg
    J2941Injection, somatropin, 1 mg
    S9558Home injectable therapy; growth hormone, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem
    ICD-10 codes covered if selection criteria are metICD-10Covered
    E23.0Hypopituitarism
    E22.0Acromegaly and pituitary gigantism
    P05.10Newborn small for gestational age
    Q96.0Turner's syndrome
    R62.52Short stature (child) [covered for SHOX deficiency in children whose epiphyses are not closed]
    ICD-10 codes not covered for indications listed in the CPBICD-10Not Covered
    F64.0Gender identity disorders [transitioning to male]
    G12.21Amyotrophic lateral sclerosis
    I50.20Congestive heart failure
    GH stimulation and diagnostic CPT codesCPTCovered
    80428-80430Growth hormone stimulation panel (e.g., arginine infusion, l-dopa administration) or growth hormone suppression panel (glucose administration)
    80435Insulin tolerance panel; for growth hormone deficiency
    82946Glucagon tolerance test
    ICD-10 codes listed as covered if selection criteria met (not all-inclusive)ICD-10
    Q87.11Prader-Willi syndrome
    Q87.19Other congenital malformation syndromes predominantly associated with short stature
    Q89.2Congenital malformations of other endocrine glands
    Q96.0-Q96.9Turner's syndrome
    R62.52Short stature (child)
    R62.7Adult failure to thrive
    R64Cachexia
    T66.xxx+Radiation sickness, unspecified
    Z92.3Personal history of irradiation
    ICD-10 examples listed as not covered for CPB indicationsICD-10Not Covered
    E66.0-E66.9Overweight and obesity (listed as not covered for indications in CPB)
    E34.30-E34.39Short stature due to endocrine disorder [Laron syndrome] (listed as not covered)
    F30.10-F33.9Episodic mood disorders (listed as not covered)
    G12.21Amyotrophic lateral sclerosis (listed as not covered)
    inv-76: BMI thresholds
    Serostim (HIV-associated wasting) initiation BMIBMI < 18.5 kg/m2 required prior to initiating Serostim
    Serostim continuation BMICurrent BMI < 27 kg/m2 required for continuation
    Glucagon test BMI-based cutoffs (referenced)Glucagon stimulated GH thresholds vary by BMI (examples: ≤3.0 ng/mL for BMI ≤30 kg/m2 with high pretest probability; ≤1.0 ng/mL for BMI ≥25 kg/m2 with low pretest probability)
    inv-77: Pediatric age limits
    Somapacitan (Sogroya) pediatric minimum ageApproved/criteria apply to pediatric patients 2.5 years of age and older
    Lonapegsomatropin (Skytrofa) pediatric minimum ageApproved/criteria apply to pediatric patients 1 year of age and older (and ≥11.5 kg per label)
    Product-specific age noteSomapacitan labeling expanded to children ≥2.5 years (REAL4); Skytrofa approved for ≥1 year based on heiGHt trial
    inv-78: Macimorelin diagnostic GH cutoff
    Macimorelin diagnostic cutoffMaximally stimulated serum GH < 2.8 ng/mL at the 30, 45, 60 and 90 minute timepoints confirms adult GHD
    Macimorelin dosing noteRecommended single oral dose 0.5 mg/kg after fasting; dose must not exceed 0.5 mg/kg per test guidance
    Macimorelin patient criteriaIndicated for adults ≥18 years with BMI ≤40 kg/m2 and prescribed by an endocrinologist when other tests are contraindicated
    inv-79: Provocative GH test peak
    Pediatric provocative GH peak thresholdPediatric: peak GH < 10 ng/mL on provocative testing is considered deficient
    Adult ITT cutoff exampleInsulin tolerance test (ITT) peak GH ≤ 5 ng/mL often used as deficient cutoff in adults
    Glucagon test cutoffs by BMIGlucagon stimulation: ≤3.0 ng/mL for BMI ≤30 kg/m2 (high pretest probability) or ≤1.0 ng/mL for BMI ≥25 kg/m2 with low pretest probability
    inv-80: Macrilen stimulated GH cutoff
    Macrilen (macimorelin) stimulated GH cutoffA maximally stimulated GH level < 2.8 ng/mL following macimorelin confirms adult GHD
    Macrilen sampling timepointsSerum GH measured at 30, 45, 60 and 90 minutes after administration
    ValidationClinical study validated macimorelin cutoff vs ITT (2.8 ng/mL macimorelin cut-point) with high reproducibility
    inv-81: General adult GH deficiency cutoff (assay-dependent)
    General adult GH deficiency example cutoffValues less than approximately 3 ng/mL (assay-dependent; example using polyclonal competitive radioimmunoassay) are considered indicative of GHD in adults
    Assay-dependence noteCutoffs vary by assay and patient factors (age, weight); use laboratory-specific reference ranges when available
    Clinical correlation requiredDiagnosis should combine provocative testing results with clinical context and IGF-1 measurements per guidelines
    inv-82: Children/adolescents stimulated GH threshold
    Children/adolescents stimulated GH thresholdStimulated peak GH < 10 ng/mL on two provocative tests (or per product criteria) is considered diagnostic of pediatric GHD
    Test repetition requirementChildren with suspected isolated GHD should have two different provocative tests showing peak <10 ng/mL unless neonatal documentation or structural CNS disorder present
    Epiphyseal statusEpiphyses must be open for pediatric treatment initiation and continuation per product criteria
    inv-83: IGF-1 deficiency threshold
    IGF-1 deficiency thresholdIGF-1 ≤ -2 SDS (2 standard deviations below mean for age/sex) defines IGF-1 deficiency in referenced studies/policy
    Laboratory reference recommendationUse the laboratory's own age/sex reference ranges to determine whether IGF-1 is ≤ -2 SDS; a provided table may be used if lab ranges unavailable
    Documentation guidanceWhen evaluating low IGF-1, document pubertal status, birth size (SGA vs AGA), bone age, and GH secretion assessment
    inv-84: Height SDS change example
    Height SDS change example (PHP-Ia cohort)Example cohort of prepubertal PHP-Ia children increased height SDS from -2.4 ± 0.58 to -1.8 ± 0.47 after 12 months of rhGH therapy
    Sustained effect notesHeight SDS improvements were maintained in subsequent years though near-adult height did not always improve due to reduced pubertal spurt
    Therapeutic timing implicationAuthors recommend early initiation of GH in PHP-Ia due to limited effective therapeutic window
    inv-85: BMI classification
    BMI classification — UnderweightBMI < 18.5 kg/m2
    BMI classification — Normal weightBMI 18.5–24.9 kg/m2
    BMI classification — OverweightBMI 25–29.9 kg/m2
    BMI classification — Obesity class 1BMI 30–34.9 kg/m2
    BMI classification — Obesity class 2BMI 35–39.9 kg/m2
    BMI classification — Extreme obesity (class 3)BMI ≥ 40 kg/m2
    inv-86: IGF-1 2 SD below mean (ng/ml)
    IGF-1 2 SD below mean — example male valuesMales: 0–5 yrs = 17 ng/mL; 6–8 = 88 ng/mL; 9–11 = 110 ng/mL; 12–15 = 202 ng/mL; 16–19 = 182 ng/mL; 20–39 = 122 ng/mL; 40–54 = 75 ng/mL; >54 = 48 ng/mL
    IGF-1 2 SD below mean — example female valuesFemales: 0–5 yrs = 17 ng/mL; 6–8 = 88 ng/mL; 9–11 = 117 ng/mL; 12–15 = 261 ng/mL; 16–19 = 182 ng/mL; 20–39 = 122 ng/mL; 40–54 = 75 ng/mL; >54 = 48 ng/mL
    Reference guidanceLaboratory-specific reference ranges are preferred; conversion factors provided for ng/mL to nmol/L if needed
    inv-87: GH stimulation test peak
    GH stimulation test peak — NormalNormal peak value: at least 10 ng/mL
    GH stimulation test peak — IndeterminateIndeterminate: 5 to 10 ng/mL
    GH stimulation test peak — SubnormalSubnormal: ≤5 ng/mL (some labs use 7 ng/mL as normal cutoff)

    Authorization, Documentation, and Monitoring Requirements

    Prior Authorization

    Precertification Required for Serostim and Somavert

    Precertification is required for Serostim (somatropin for HIV wasting) and Somavert (pegvisomant) for all Aetna participating providers and members in applicable plan designs. Call (866) 752-7021 or fax (888) 267-3277 to obtain precertification. Include a completed Statement of Medical Necessity (SMN) or use Aetna's Specialty Pharmacy Precertification forms when applicable.

    • Precertify Serostim/Somavert: call (866) 752-7021 or fax (888) 267-3277
    • Submit Statement of Medical Necessity (SMN) or Specialty Pharmacy Precertification form
    Prior Authorization

    Prior Authorization Recommended — Congestive Heart Failure

    Aetna recommends prior authorization for therapies where evidence is mixed or evolving. For congestive heart failure (CHF), meta-analyses suggest potential benefit but confirmatory large trials are lacking; prior authorization is recommended to ensure appropriate patient selection and documentation.

    • CHF: prior authorization recommended given mixed meta-analysis evidence
    Prior Authorization

    Prior Authorization for Non‑Standard Indications

    Prior authorization is required for non-standard or off-label indications (e.g., thalassemia, traumatic brain injury, HIV lipodystrophy, idiopathic short stature, other adult miscellaneous conditions). These indications are often considered experimental/investigational or require robust justification and documentation of prior therapies.

    • Non-standard indications (thalassemia, TBI, HIV lipodystrophy, ISS, etc.) require prior authorization with strong clinical rationale
    • Many of these indications are considered experimental/investigational and may be denied
    Note

    Prior Authorization References and Resources

    Refer to the main policy and references for specific prior authorization processes, code lists, and clinical criteria. The References section and product prescribing information cited throughout the policy support medical necessity determinations.

    • Consult policy references and product prescribing information for authorization criteria
    • Use Clinical Policy Bulletin references when preparing documentation
    Documentation Required

    Prior Authorization Requirements and Documentation

    Prior authorization requirements include indication-specific clinical documentation: diagnosis, treatment history, laboratory and imaging data, and documentation of trials of alternative therapies or contraindications when applicable. Failure to obtain required prior authorization or precertification may result in denial of payment.

    • Provide indication-specific protocol and justification (e.g., acromegaly, IVF adjuncts, PWS safety screening)
    • Include pretreatment IGF-1, provocative test results, genetic testing when relevant, bone age/epiphyses status, and prior therapy details
    Prior Authorization

    Precertification Requirement and Contractual Note

    A formal precertification requirement applies; failure to precertify Serostim or Somavert when required may lead to denial. Precertification is a contractual requirement in applicable plan designs.

    • Precertification is contractual for certain medications — obtain before treatment
    Denial Risk

    Contractual and Experimental/Investigational Exclusions

    Some indications are subject to contractual exclusions or are deemed experimental/investigational (e.g., idiopathic short stature, HIV lipodystrophy). Coverage may vary by benefit plan; when a diagnosis is not a disease under the plan definition (for example ISS), denial is a contractual determination rather than a medical necessity decision.

    • Contractual exclusions: ISS often not covered under plans that cover only disease/injury
    • Experimental/investigational indications may be denied
    Billing Rule

    ICD‑10 Exclusions May Trigger Denial

    Certain ICD‑10 diagnosis codes are listed as not covered for indications in this policy. Use the ICD-10 code lists in the policy when submitting authorizations; inappropriate codes may trigger denial.

    • ICD-10 exclusions include (not all-inclusive): I50.* (congestive heart failure codes), E66.* (obesity), G12.21 (ALS), P05.2 (IUGR), and many others listed in the CPT/ICD section
    • Ensure submitted ICD-10 codes align with covered indications in the CPB
    Documentation Required

    Pegvisomant (Somavert) — Liver Function and Imaging Monitoring

    For patients receiving pegvisomant (Somavert) for acromegaly, monitor liver function tests (LFTs) before treatment, monthly for the first six months, and every six months thereafter due to reports of elevated transaminases and idiosyncratic chronic active hepatitis.

    • LFTs: baseline, monthly x6 months, then every 6 months
    • Pituitary MRI every 6 months as indicated to monitor for tumor growth
    Denial Risk

    Acute Catabolism — Not Recommended; Denial Risk

    Growth hormone is not recommended for acute catabolic states (e.g., critically ill, perioperative, burn patients) because trials showed increased mortality in GH-treated critically ill patients. Such use carries a high denial risk.

    • Acute catabolism (critically ill, burns, perioperative) — GH contraindicated due to increased mortality in trials
    • Denial risk for acute catabolic indications
    Denial Risk

    Uncertain Efficacy May Trigger Denial — Evidence‑Sensitive Indications

    Use of GH for indications with uncertain or low-quality evidence (for example adjunctive GH in IVF, some miscellaneous adult conditions, HIV-associated trunkal obesity) may trigger denial or require strong justification and prior authorization.

    • Adjunctive GH to improve IVF outcomes: evidence uncertain/low certainty — require prior optimization and justification
    • HIV-associated truncal obesity/lipodystrophy: considered experimental by Aetna
    Denial Risk

    Intra‑Uterine Growth Restriction (IUGR) — Lack of Evidence

    There is insufficient evidence to support GH for intrauterine growth restriction (IUGR); clinical use is not supported and prior authorization is unlikely to be approved for this indication.

    • IUGR: lack of evidence; GH not supported for clinical use
    Documentation Required

    GH Stimulation Testing Requirements in Adults

    In adults, GH-stimulation testing requirements depend on clinical context. Testing is not required in patients with ≥3 pituitary hormone deficiencies and low IGF-1 or in specific congenital/structural conditions. Testing is required for acquired causes (pituitary tumors, surgery, irradiation, TBI, infiltrative disease, etc.). Consult Appendix C for detailed criteria.

    • Adults: no stimulation test required if ≥3 pituitary hormone deficiencies and low IGF-1 or specified congenital/structural defects
    • Adults: stimulation testing required for acquired causes (e.g., pituitary adenoma, cranial irradiation, TBI, surgery)
    Note

    Coverage Exception Noted — Idiopathic Short Stature (ISS)

    Aetna specifically notes that idiopathic short stature (ISS) is generally not covered by most plans because it is not considered a disease; ISS denials are contractual exceptions rather than medical necessity denials. Providers should verify member benefits and document plan limitations when applicable.

    • ISS: typically not a covered benefit — contractual denial possible
    • Verify member-specific plan provisions
    Note

    This Section Contains Only References — Not Authorization Criteria

    This section contains references only and is not a substitute for authorization criteria. Use the References and product prescribing information cited in the policy to support authorization requests; references do not by themselves authorize coverage.

    • References and PIs are provided to support clinical rationale but do not constitute authorization
    Note

    Clinical Policy Bulletins Are Not Offers of Coverage

    Clinical Policy Bulletins are developed to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. They are a partial, general description of plan benefits; providers remain responsible for treatment decisions and must verify plan-specific coverage.

    • CPBs are not offers of coverage; they do not replace the benefit contract
    • Providers are responsible for medical advice and for verifying member benefits
    Documentation Required

    IGF‑1 Monitoring and Dosing Documentation

    Document IGF-1 monitoring, dose titration, injection-site rotation, and adverse event surveillance in the medical record. For adults, start at low GH doses and titrate monthly using IGF-1 levels to guide dosing. For once-weekly agents, follow product-specific titration schedules and IGF-1 monitoring protocols.

    • Record baseline and follow-up IGF-1 values referenced to age/sex laboratory ranges
    • Document monthly assessments during titration and subsequent monitoring per product labeling
    • Rotate injection sites and record any adverse events
    Documentation Required

    18p Deletion Syndrome — Genetic and Endocrine Documentation Required

    For rare genetic conditions such as 18p deletion syndrome, include genetic testing reports and endocrine evaluations when requesting authorization for GH therapy. Demonstrate response when possible (growth metrics) and provide specialist endocrinology consultation notes.

    • Attach genetic testing results (e.g., cytogenetic/SNP array) and endocrine evaluation
    • Provide pre- and on-treatment growth data showing response to therapy
    Documentation Required

    Glucocorticoid‑Induced Growth Failure — Documentation Expectations

    For glucocorticoid-induced growth failure, document duration and dose of glucocorticoid therapy, baseline growth metrics, and GH treatment duration and response. Clinical data from registries demonstrate response often requires >12 months of combined therapy; include monitoring of glucose and metabolic parameters.

    • Document GC dose/duration and baseline/follow-up height/height velocity and IGF-1
    • Monitor glucose, insulin, and HbA1c as indicated during GH therapy
    Prior Authorization

    Serostim Authorization — Alternative Therapy Trial and Documentation

    For Serostim (HIV wasting), document that the member is on antiretroviral therapy and has had trial of alternative therapies with suboptimal response or documented contraindication/intolerance. Record pretreatment BMI (<18.5 kg/m2) and ongoing monitoring for continuation criteria (BMI <27 kg/m2 for continued therapy).

    • Serostim initial: on ART, trial of alternatives or contraindication, pretreatment BMI <18.5 kg/m2
    • Serostim continuation: currently on ART, receiving Serostim, current BMI <27 kg/m2
    • Alternative therapies to document prior trial: cyproheptadine, dronabinol, megestrol, testosterone if hypogonadal
    Step Therapy

    Therapy Sequencing for Acromegaly and Pegvisomant Step Therapy

    For acromegaly, document sequencing of therapies: prior inadequate response to surgery or radiotherapy (or clinical reason surgery/radiation not appropriate) before initiating pegvisomant (Somavert). For pegvisomant, provide baseline IGF-1 and planned monitoring (IGF-1 response, LFTs, pituitary imaging).

    • Document prior surgery and/or radiotherapy and response before Somavert
    • Provide baseline IGF-1 and plan for IGF-1 and LFT monitoring and pituitary MRI surveillance
    Documentation Required

    Trial and Titration Expectations — GH and Once‑Weekly Agents

    Expectation for trial and titration: start GH at low dose in adults and titrate monthly based on clinical response and IGF-1. For once-weekly agents (e.g., somapacitan, lonapegsomatropin), follow product-specific initiation and titration schedules and IGF-1-guided dosing adjustments.

    • Adult GH start: low dose (e.g., 0.1–0.4 mg/day) with monthly assessments
    • Once-weekly agents: follow labeled initiation and titration intervals; titrate to IGF-1 targets
    Step Therapy

    SGA/SRS and Pegvisomant Step and Termination Guidance

    For pegvisomant step/termination guidance and for SGA/SRS therapy, follow consensus dosing and termination considerations: use recommended dosing ranges, titrate to IGF-1 targets, and consider stopping GH when growth velocity thresholds or bone age criteria are met per consensus statements.

    • SGA/SRS: follow consensus for dosing and termination (e.g., stop when height velocity <2 cm/year and bone age >14F/>17M)
    • Pegvisomant: titrate to normalize IGF-1 and reassess need for continuation
    Step Therapy

    Step Therapy Considerations and Requirement to Optimize Standard Treatments

    Consider step therapy or alternative less costly treatments before GH in conditions where alternatives exist (e.g., constitutional delay: consider testosterone/anabolics in males or low‑dose estrogen in females). Document trials of standard optimization before authorizing GH adjuncts for IVF or Crohn's disease-related growth failure.

    • Constitutional delay: document trial of alternatives prior to GH
    • IVF adjuncts: require optimization of standard IVF protocols before GH
    • Crohn's disease: ensure nutritional optimization prior to GH
    Denial Risk

    HIV‑Associated Truncal Obesity and Alternative Therapies

    For HIV-associated truncal obesity and lipodystrophy, sequence treatments and document prior trials. Aetna considers GH for HIV lipodystrophy experimental; alternative therapies (see Appendix E) should be trialed and documented when managing HIV‑related wasting vs truncal obesity.

    • HIV‑associated truncal obesity: GH considered experimental for lipodystrophy — document rationale if requested
    • Alternative agents for HIV wasting/loss of lean mass: cyproheptadine, dronabinol (Marinol), megestrol acetate, testosterone if hypogonadal
    Prior Authorization

    Adult Miscellaneous Conditions — Prior Authorization Likely

    For adult miscellaneous conditions where evidence is limited (e.g., age‑related bone loss, chronic catabolic states), prior authorization is likely required and long‑term GH therapy is generally not recommended without strong justification and supporting data.

    • Adult miscellaneous conditions: limited evidence; prior authorization and strong justification required
    • Long‑term GH therapy not routinely supported for many adult indications
    Documentation Required

    Alternative Therapies for HIV Wasting (Appendix E)

    Appendix E lists alternative therapies for HIV wasting which should be trialed prior to Serostim when appropriate: cyproheptadine, dronabinol (Marinol), megestrol acetate (Megace), and testosterone therapy if hypogonadal.

    • Appendix E alternatives: cyproheptadine; dronabinol (Marinol); megestrol acetate (Megace); testosterone if hypogonadal

    Background and Scope

    Background: Growth hormone (somatropin) products are FDA‑approved for pediatric and adult growth hormone deficiency and selected other conditions (for example, Turner syndrome, Prader‑Willi syndrome, small for gestational age, short‑bowel syndrome, and HIV‑associated wasting). Long‑acting weekly GH formulations (e.g., somapacitan, lonapegsomatropin) and GH receptor antagonists (pegvisomant) have product‑specific approvals and safety considerations summarized in the policy. The bulletin outlines diagnostic requirements, testing thresholds, age/weight limits, dosing and monitoring expectations, and contraindications for these agents.

    inv-144: Pediatric GH deficiency — diagnostic summary (neonatal documentation, provocative tests, IGF-1)
    Pediatric GH deficiency diagnostic summaryDiagnosis: either neonatal documentation of GHD OR two failed provocative GH tests (both peaks <10 ng/mL) OR documented pituitary/CNS disorder with pretreatment IGF-1 >2 SD below mean plus growth/height velocity thresholds and open epiphyses
    Neonatal documentation examplesSupportive records include hypoglycemia with random GH, evidence of multiple pituitary hormone deficiency, clinic notes, or MRI findings
    Testing recommendationFor suspected isolated GHD in children, perform two different provocative tests after excluding hypothyroidism
    inv-145: Provocative GH test thresholds
    Provocative test examples and thresholdsExamples: ITT peak GH ≤5 ng/mL; macimorelin (Macrilen) peak <2.8 ng/mL; glucagon stimulation thresholds vary by BMI (≤3.0 ng/mL or ≤1.0 ng/mL depending on BMI and pretest probability)
    Testing contextThresholds depend on test modality, BMI, and pretest probability; use appropriate cutoffs per policy and lab assay
    Two-test requirement for childrenChildren typically require two different provocative tests both showing deficient peaks unless neonatal diagnosis or structural cause documented
    inv-146: Macimorelin stimulation test — oral test for adults 18+ with BMI ≤40 when other tests contraindicated
    Macimorelin test indicationOral macimorelin stimulation test is indicated for adults ≥18 years with BMI ≤40 kg/m2 when other tests (ITT, glucagon, arginine, clonidine, levodopa) are contraindicated
    Dosage and administrationRecommended dose 0.5 mg/kg as single oral dose after at least 8 hours fasting; do not exceed 0.5 mg/kg
    Diagnostic cutpointSerum GH <2.8 ng/mL at 30, 45, 60 and 90 minutes confirms AGHD per validation studies
    inv-147: Pediatric GH deficiency diagnostic criteria — neonatal diagnosis or two failed provocative tests or structural CNS disorder
    Pediatric diagnostic pathwaysEither neonatal diagnosis with supporting records, or two failed provocative tests (peak <10 ng/mL) or structural CNS/pituitary disorder with low IGF-1 and growth/height velocity criteria
    Open epiphyses requirementEpiphyses must be open for initiation/continuation in pediatric patients (confirm by X-ray if needed)
    Age-specific velocity thresholdsFor <2.5 yrs: pretreatment height >2 SD below mean plus slow growth velocity; for ≥2.5 yrs: height >2 SD and 1-year velocity >1 SD below mean OR 1-year velocity >2 SD below mean
    inv-148: Adult Growth Hormone Deficiency (AGHD) — syndrome description and clinical features
    AGHD syndrome descriptionAdult GHD presents with reduced lean mass and bone density, increased fat mass (abdominal adiposity), reduced muscle strength, impaired exercise performance, and reduced quality of life
    Evaluation indicationsEvaluate for AGHD in members with hypothalamic-pituitary disease, prior cranial irradiation, or childhood-onset GHD
    Diagnosis requires provocative testingDiagnosis established by provocative testing (e.g., ITT) or validated alternatives with assay- and BMI-adjusted cutoffs
    inv-149: Macrilen (macimorelin) diagnostic cutoff — <2.8 ng/mL
    Macrilen (macimorelin) diagnostic cutoff summaryMacimorelin: stimulated GH <2.8 ng/mL confirms adult GHD per validation study; reproducibility ~97% in retesting
    Test performanceMacimorelin results comparable to ITT with good sensitivity and specificity; sampling at 30–90 minutes post-dose
    Clinical utilityUseful oral alternative when ITT is contraindicated or impractical
    inv-150: Somapacitan (Sogroya) — definition and weekly administration note
    Somapacitan (Sogroya) definitionOnce-weekly reversible albumin-binding GH derivative approved for adult AGHD (2020) and expanded to pediatric GHD (label details in policy)
    Administration and titrationAdministered subcutaneously once weekly; initiation 1.5 mg weekly with titration by IGF-1 and clinical response; max 8 mg weekly
    Pediatric expansion noteLabel expanded to pediatric patients ≥2.5 years per REAL4 trial (referenced in policy)
    inv-151: Lonapegsomatropin (Skytrofa) — definition and pediatric approval details
    Lonapegsomatropin (Skytrofa) definitionOnce-weekly pegylated sustained-release somatropin approved for pediatric GHD (≥1 year and ≥11.5 kg); dosing individualized (0.24 mg/kg/week used in trials)
    Clinical trial basisApproval based on heiGHt trial showing noninferiority and a 0.9 cm/year higher AHV vs daily somatropin at 52 weeks
    Age/weight requirementsLabel specifies pediatric patients 1 year and older who weigh at least 11.5 kg
    inv-152: Pegvisomant (Somavert) — GH receptor antagonist definition and monitoring considerations
    Pegvisomant (Somavert) definitionGH receptor antagonist indicated for acromegaly patients with inadequate response to surgery or radiation; normalizes IGF-1 in most patients
    Monitoring considerationsMonitor pituitary MRI every 6 months and liver function tests before and monthly for first 6 months, then every 6 months due to hepatotoxicity risk (transaminase elevations reported)
    Safety signalsIdiosyncratic chronic active hepatitis reported; transaminase elevations >3x ULN noted in ~9% with long-term use
    inv-153: SHOX deficiency (SHOX-D) — definition
    SHOX deficiency definitionMutation or deletion of the SHOX gene causing impaired long-bone growth and variable short stature with skeletal anomalies
    Diagnosis requirementDiagnosis confirmed by molecular or genetic analysis per policy when used to justify GH therapy
    Therapeutic response noteRandomized trial data show significant increases in height velocity and height SDS in molecularly proven SHOX deficiency
    inv-154: Turner syndrome (TS) — definition
    Turner syndrome definitionChromosomal condition (complete or partial absence of second X chromosome) frequently associated with short stature
    GH dosing noteSupra-physiological GH doses typically required; usual pediatric dose 0.045–0.050 mg/kg/day
    Treatment initiationOften initiated when height SDS decreases to less than -2; individualized decisions based on height and growth velocity
    inv-155: Acute catabolism — definition and examples
    Acute catabolism definitionConditions such as critical illness, perioperative states, and burns associated with metabolic stress where GH has been shown to increase mortality in trials
    Coverage stanceGH is not recommended for treatment of acute catabolic states due to higher mortality observed in clinical trials
    Clinical implicationUse in these settings should be avoided outside research contexts
    inv-156: Glucocorticoid-induced growth failure — definition
    Glucocorticoid-induced growth failure definitionGrowth suppression during long-term glucocorticoid therapy characterized by reduced GH release and IGF‑I activity; GH therapy may improve growth metrics
    Observed trial resultsIn a series (n=83) mean growth rate increased from ~3.0 cm/yr to ~6.3 cm/yr after 12 months on GH; height SDS improved by 0.21 ± 0.4
    Monitoring during therapyMonitoring included IGF‑I, IGFBP‑3, glucose, insulin, procollagen, osteocalcin, and HbA1c in cited evaluations
    inv-157: Idiopathic short stature (ISS) — definition and payer stance
    Idiopathic short stature (ISS) definitionChildren ≥2 SD below mean height with normal GH stimulation results and no identifiable disease cause; Aetna does not consider ISS a disease
    Coverage stanceTreatment of ISS considered an enhancement (appearance/performance) and generally not medically necessary under Aetna plans
    Efficacy magnitudeGH may increase final height modestly (2–7 cm) in ISS populations per trials, but functional benefit is unproven
    inv-158: HIV-associated lipodystrophy — definition
    HIV-associated lipodystrophy definitionDisorder of fat metabolism in HIV patients characterized by changes in visceral and subcutaneous fat distribution and metabolic derangements
    Effect of GH-axis drugsGH-axis treatments decreased visceral adipose tissue and increased lean body mass in RCTs but produced side effects (arthralgias, edema)
    Coverage stanceAetna considers GH treatment for HIV-associated lipodystrophy experimental and investigational
    inv-159: Primary IGF‑1 deficiency (IGFD) — definition
    Primary IGF‑1 deficiency (IGFD) definitionLow IGF‑1 levels without concomitant impairment in GH secretion and no secondary cause; study-defined IGF1-deficient as IGF1 ≤ -2 SDS
    Prevalence noteIn one retrospective prepubertal isolated short stature cohort, ~20% had IGF-1 ≤ -2 SDS consistent with primary IGFD
    Diagnostic documentationWhen evaluating IGF‑1 deficiency document IGF‑1, GH secretion assessment, pubertal status, birth size, and bone age
    inv-160: Poor ovarian responder (POR) — definition in IVF context
    Poor ovarian responder (POR) definitionPatient subgroup in IVF trials characterized by reduced ovarian response to stimulation; many GH studies target this population
    Evidence summaryMeta-analyses report variable increases in oocytes/clinical pregnancy but very uncertain effects on live birth; evidence quality often low
    Payer implicationRoutine GH adjunctive use in IVF is not supported by high-certainty evidence; prior authorization should require indication-specific protocol
    inv-161: Primary IGF-1 deficiency (IGFD) — study-defined IGF1 ≤ -2 SDS
    Study-defined IGF1-deficient thresholdIGF1 ≤ -2 SDS used in study definitions to identify primary IGF-1 deficiency in isolated short stature cohorts
    Diagnostic workupExclude secondary causes and assess GH secretion and pubertal status when IGF1 ≤ -2 SDS
    Clinical implicationsSome IGF-1 deficient children may have delayed bone age or nutritional/maturational delay rather than primary endocrine defect
    inv-162: Congenital genetic abnormalities — examples of transcription factor defects
    Examples of congenital genetic abnormalitiesTranscription factor defects (PIT-1, PROP-1, LHX3/4, HESX-1, PITX-2), GHRH receptor defects, GH secretagogue receptor defects, GH gene defects, GH receptor/post-receptor defects
    Clinical relevanceThese genetic defects are listed as examples of hypothalamic/pituitary disorders that may underlie childhood-onset GHD
    Diagnostic pathwayPresence of congenital genetic abnormalities can obviate need for repeated provocative testing per policy pathways
    inv-163: Congenital structural abnormalities — examples
    Examples of congenital structural abnormalitiesOptic nerve hypoplasia/septo-optic dysplasia; agenesis of corpus callosum; empty sella; ectopic posterior pituitary; pituitary aplasia/hypoplasia; pituitary stalk defect; holoprosencephaly; encephalocele; hydrocephalus
    Clinical implicationDocumented structural abnormalities in CNS/pituitary support diagnostic pathways for GH therapy without requiring two provocative tests in some cases
    Appendix referenceAppendix A and C list congenital structural/genetic causes relevant to diagnosis

    Policy Revisions and Notes

    2023-04label_expansionLatest

    FDA approved pediatric label expansion for somapacitan (Sogroya) for treatment of pediatric patients aged 2.5 years and older based on the REAL4 trial showing comparable annualized height velocity to daily somatropin.

    2020-08-28approval

    FDA approved once-weekly somapacitan (Sogroya) for replacement of endogenous growth hormone in adults with growth hormone deficiency based on the REAL1 trial.

    2021-08approval

    FDA approved lonapegsomatropin (Skytrofa) for pediatric growth hormone deficiency for children ≥1 year and ≥11.5 kg based on the phase 3 heiGHt trial (approval noted in policy background).

    1997-08-14policy_effective

    Policy effective date for Aetna’s Clinical Policy Bulletin on growth hormone therapies as recorded in the policy metadata.

    2023-07-28policy_review

    Policy last reviewed on 2023-07-28 per the document metadata.

    Policy core summary dates: this Clinical Policy Bulletin is effective as of 08/14/1997, with the last review on 07/28/2023 and the next review scheduled for 03/28/2024.